Sean Bohen - Sep 21, 2022 Form 4/A - Amendment Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Sep 21, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/23/2022, 05:35 PM
Date Of Original Report
Sep 22, 2022
Previous filing
Feb 3, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Purchase +20K +36.85% 74.3K Sep 21, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed solely to correct the transaction code in column 3 of Table I from code "A" to code "P".
F2 The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3 Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan.